Home
SLRN
SLRN News

Latest ACELYRIN INC. (SLRN) News on May 14, 2025

WEX, Acelyrin, and More Stocks See Action From Activist Investors

Barrons.com

5 days ago

WEX, Acelyrin, and More Stocks See Action From Activist Investors

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

GlobeNewswire

8 days ago

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

Acelyrin urges stockholders to vote for proposed merger with Alumis

TipRanks

12 days ago

Acelyrin urges stockholders to vote for proposed merger with Alumis

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

GlobeNewswire

13 days ago

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

May 2025's Rising Stars: Three Penny Stocks To Consider

Simply Wall St.

13 days ago

May 2025's Rising Stars: Three Penny Stocks To Consider

Acelyrin should liquidate instead of merging with Alumis, investor says

BioPharma Dive

15 days ago

Acelyrin should liquidate instead of merging with Alumis, investor says

MT Newswires

23 days ago

Alumis Raises Share Consideration for Acelyrin Acquisition

Alumis and ACELYRIN Announce Amended Merger Agreement

GlobeNewswire

23 days ago

Alumis and ACELYRIN Announce Amended Merger Agreement

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

GlobeNewswire

a month ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now

Insider Monkey

2 months ago

Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

BioPharma Dive

2 months ago

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

MT Newswires

2 months ago

Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

GlobeNewswire

2 months ago

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

3 Promising Penny Stocks With Over $100M Market Cap

Simply Wall St.

2 months ago

3 Promising Penny Stocks With Over $100M Market Cap

Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?

Insider Monkey

2 months ago

Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?

MT Newswires

2 months ago

Sector Update: Health Care Stocks Lower Tuesday Afternoon

MT Newswires

2 months ago

Acelyrin Reaffirms Merger Deal With Alumis

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

GlobeNewswire

2 months ago

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

GlobeNewswire

2 months ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

GlobeNewswire

2 months ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

BioPharma Dive

2 months ago

Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

BioPharma Dive

3 months ago

Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

MT Newswires

3 months ago

Acelyrin Receives Unsolicited Buyout Offer From Concentra Biosciences

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

GlobeNewswire

3 months ago

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

3 US Penny Stocks With Market Caps Over $30M To Watch

Simply Wall St.

3 months ago

3 US Penny Stocks With Market Caps Over $30M To Watch

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

GlobeNewswire

3 months ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

GlobeNewswire

4 months ago

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

Acelyrin Leads The Charge With 2 Other US Penny Stocks

Simply Wall St.

4 months ago

Acelyrin Leads The Charge With 2 Other US Penny Stocks

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

GlobeNewswire

4 months ago

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

GlobeNewswire

5 months ago

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

Promising US Penny Stocks To Consider In November 2024

Simply Wall St.

6 months ago

Promising US Penny Stocks To Consider In November 2024

GuruFocus.com

6 months ago

Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ...

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire

6 months ago

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

GlobeNewswire

6 months ago

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

GlobeNewswire

7 months ago

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

GlobeNewswire

8 months ago

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc

GuruFocus.com

8 months ago

Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery

GlobeNewswire

8 months ago

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

GlobeNewswire

9 months ago

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

GlobeNewswire

9 months ago

ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

Why Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now?

Insider Monkey

9 months ago

Why Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now?

ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

GlobeNewswire

9 months ago

ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

Here's Why We're Watching Acelyrin's (NASDAQ:SLRN) Cash Burn Situation

Simply Wall St.

10 months ago

Here's Why We're Watching Acelyrin's (NASDAQ:SLRN) Cash Burn Situation

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Simply Wall St.

a year ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

Simply Wall St.

a year ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Motley Fool

a year ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Simply Wall St.

a year ago

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Simply Wall St.

a year ago

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Seoul resumes loudspeaker propaganda against North

AFP

a year ago

Seoul resumes loudspeaker propaganda against North

ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024

GlobeNewswire

a year ago

ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

GlobeNewswire

a year ago

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

GlobeNewswire

a year ago

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

ACELYRIN, INC. Announces Leadership Transition

GlobeNewswire

a year ago

ACELYRIN, INC. Announces Leadership Transition

ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

GlobeNewswire

a year ago

ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

Acelyrin Insiders Placed Bullish Bets Worth US$2.65m

Simply Wall St.

a year ago

Acelyrin Insiders Placed Bullish Bets Worth US$2.65m

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

GlobeNewswire

a year ago

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

GlobeNewswire

a year ago

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

GlobeNewswire

a year ago

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

GlobeNewswire

a year ago

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

GlobeNewswire

a year ago

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

GlobeNewswire

a year ago

ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

Baldinger: How 49ers HC Kyle Shanahan creates numbers advantage for McCaffrey in run game

NFL Highlights

a year ago

Baldinger: How 49ers HC Kyle Shanahan creates numbers advantage for McCaffrey in run game

SunCoke Energy, Inc. (NYSE:SXC) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

SunCoke Energy, Inc. (NYSE:SXC) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q4 2023 LendingClub Corp Earnings Call

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 01/31/2024

LendingClub (LC) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

a year ago

LendingClub (LC) Reports Q4 Earnings: What Key Metrics Have to Say

Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Simply Wall St.

a year ago

Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Monro (NASDAQ:MNRO) Misses Q3 Revenue Estimates

StockStory

a year ago

Monro (NASDAQ:MNRO) Misses Q3 Revenue Estimates

HCI Group Takes Strategic Steps to Better Position Company for Future Opportunities

GlobeNewswire

a year ago

HCI Group Takes Strategic Steps to Better Position Company for Future Opportunities

Associated Press Finance

a year ago

OceanFirst: Q4 Earnings Snapshot

OceanFirst Financial Corp. Announces Quarterly and Annual Earnings and Financial Results

GlobeNewswire

a year ago

OceanFirst Financial Corp. Announces Quarterly and Annual Earnings and Financial Results

Associated Capital Reports Estimated Fourth Quarter and Full Year Results

GlobeNewswire

a year ago

Associated Capital Reports Estimated Fourth Quarter and Full Year Results

Green Plains Inc. Completes Acquisition of Green Plains Partners LP

Business Wire

a year ago

Green Plains Inc. Completes Acquisition of Green Plains Partners LP

NETSTREIT Corp. Announces Launch of Public Offering of Common Stock

Business Wire

a year ago

NETSTREIT Corp. Announces Launch of Public Offering of Common Stock

GlobeNewswire

a year ago

iHeartMedia and Magnite Unify Access to Broadcast and Digital Audio, Providing Advertisers with a Direct Path to Premium Inventory

ECARX Announces Board Changes

GlobeNewswire

a year ago

ECARX Announces Board Changes

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Zacks

a year ago

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Magnite, Inc.'s (NASDAQ:MGNI) recent 6.4% pullback adds to one-year year losses, institutional owners may take drastic measures

Simply Wall St.

a year ago

Magnite, Inc.'s (NASDAQ:MGNI) recent 6.4% pullback adds to one-year year losses, institutional owners may take drastic measures

BioCryst Pharmaceuticals (NASDAQ:BCRX) investors are sitting on a loss of 48% if they invested a year ago

Simply Wall St.

a year ago

BioCryst Pharmaceuticals (NASDAQ:BCRX) investors are sitting on a loss of 48% if they invested a year ago

Estimating The Intrinsic Value Of Ramaco Resources, Inc. (NASDAQ:METC)

Simply Wall St.

a year ago

Estimating The Intrinsic Value Of Ramaco Resources, Inc. (NASDAQ:METC)

Are Robust Financials Driving The Recent Rally In Myers Industries, Inc.'s (NYSE:MYE) Stock?

Simply Wall St.

a year ago

Are Robust Financials Driving The Recent Rally In Myers Industries, Inc.'s (NYSE:MYE) Stock?

Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?

Zacks

a year ago

Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?

ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

GlobeNewswire

a year ago

ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

With 65% ownership, Two Harbors Investment Corp. (NYSE:TWO) boasts of strong institutional backing

Simply Wall St.

a year ago

With 65% ownership, Two Harbors Investment Corp. (NYSE:TWO) boasts of strong institutional backing

12 Most Promising Cancer Stocks According to Analysts

Insider Monkey

a year ago

12 Most Promising Cancer Stocks According to Analysts

Stock Yards Bancorp Inc's Dividend Analysis

GuruFocus.com

a year ago

Stock Yards Bancorp Inc's Dividend Analysis

Cohen & Steers Closed-End Funds Declare Distributions for January, February, and March 2024

PR Newswire

a year ago

Cohen & Steers Closed-End Funds Declare Distributions for January, February, and March 2024

Business Wire

a year ago

Community Trust Bancorp, Inc. Announces Retirement of James J. Gartner

Sphere Stock Gets an Upgrade After an Ugly Day

Barrons.com

a year ago

Sphere Stock Gets an Upgrade After an Ugly Day

Genesis Energy, L.P. to Participate in the 2023 Wells Fargo Midstream & Utilities Symposium

Business Wire

a year ago

Genesis Energy, L.P. to Participate in the 2023 Wells Fargo Midstream & Utilities Symposium

Tidewater Utilities Announces Promotion

GlobeNewswire

a year ago

Tidewater Utilities Announces Promotion

ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program

GlobeNewswire

a year ago

ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Calumet Specialty Products Partners LP Earnings Call

ACCESSWIRE

2 years ago

Loma Negra 3Q23

Top Dividend Stocks: A Sizzling 8.8% Yield Highlights This Commercial REIT

Investor's Business Daily

2 years ago

Top Dividend Stocks: A Sizzling 8.8% Yield Highlights This Commercial REIT

Is Now An Opportune Moment To Examine Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE:LOMA)?

Simply Wall St.

2 years ago

Is Now An Opportune Moment To Examine Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE:LOMA)?

GuruFocus.com

2 years ago

Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing

ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire

2 years ago

ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights

Share on Social Networks: